title: Conservative treatment in epithelial ovarian cancer: results of a multicentre study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le Cancer) and SFOG (Société Francaise d'Oncologie Gynécologique).
abstract: BACKGROUND
  Results of conservative management of epithelial ovarian cancer (EOC) remain controversial in the literature. The aim of this study was to assess the clinical outcomes and fertility following fertility-sparing surgical management of EOC in a retrospective multicentre study.
  
  
  METHODS
  A multicentre retrospective study was performed by members of two French groups. Six inclusion criteria were defined: (i) Histological review by the same pathologist; (ii) age < or =40 years; (iii) conservative management; (iv) complete peritoneal staging; (v) delivery of a platinum-based chemotherapy in stage > or = IC; and (vi) follow-up >1 year.
  
  
  RESULTS
  Thirty-four patients fulfilled the inclusion criteria: 30 had stage IA disease; three had stage IC and one had stage IIA. Eleven patients had recurrence: 10 patients had invasive disease and one had borderline recurrence. Among 10 patients with invasive recurrence, initial stage and grade were: stage IA G1, n = 1; stage IA G2, n = 4; stage IA G3, n = 1; and stage> or = IC, n = 4. All patients with stage > IA had recurrence. Ten pregnancies were observed in nine patients.
  
  
  CONCLUSIONS
  Conservative surgery for patients with EOC could be considered in young patients with stage IA G1 disease. This procedure should not be performed in patients with FIGO stage > IA.
authors.affiliation: Institut Gustave Roussy, Villejuif, France. morice@igr.fr
authors.forename: Philippe
authors.initials: P
authors.lastname: Morice
authors.forename: Eric
authors.initials: E
authors.lastname: Leblanc
authors.forename: Annie
authors.initials: A
authors.lastname: Rey
authors.forename: Marc
authors.initials: M
authors.lastname: Baron
authors.forename: Denis
authors.initials: D
authors.lastname: Querleu
authors.forename: Jérôme
authors.initials: J
authors.lastname: Blanchot
authors.forename: Pierre
authors.initials: P
authors.lastname: Duvillard
authors.forename: Catherine
authors.initials: C
authors.lastname: Lhommé
authors.forename: Damienne
authors.initials: D
authors.lastname: Castaigne
authors.forename: Jean Marc
authors.initials: JM
authors.lastname: Classe
authors.forename: Pascal
authors.initials: P
authors.lastname: Bonnier
mesh_terms: D000293:Adolescent; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D005260:Female; D005298:Fertility / Q000502:physiology; D005500:Follow-Up Studies; D006801:Humans; D007044:Hysterectomy; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D009375:Neoplasms, Glandular and Epithelial / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D010053:Ovary / Q000502:physiology; D010984:Platinum / Q000627:therapeutic use; D011247:Pregnancy; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D000970:Antineoplastic Agents; D010984:Platinum